These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22476156)

  • 21. [Triple combination treatment of chronic hepatitis C].
    Husa P
    Vnitr Lek; 2012; 58(7-8):588-90. PubMed ID: 23067190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors.
    Miotto N; Mendes LC; Zanaga LP; Goncales ES; Lazarini MS; Pedro MN; Goncales FL; Stucchi RS; Vigani AG
    Braz J Med Biol Res; 2016 Jun; 49(7):. PubMed ID: 27356107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Boceprevir: a protease inhibitor for the treatment of hepatitis C.
    Chang MH; Gordon LA; Fung HB
    Clin Ther; 2012 Oct; 34(10):2021-38. PubMed ID: 22975763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Combined telaprevir plus ribavirin and pegylated interferon therapy for patients with chronic hepatitis C].
    Mochida S
    Nihon Rinsho; 2015 Feb; 73(2):259-65. PubMed ID: 25764680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Telaprevir: looking for a sustained virologic response in hepatitis C virus infection.
    Nehra V; Rizza SA; Talwani R; Temesgen Z
    Drugs Today (Barc); 2011 Nov; 47(11):829-37. PubMed ID: 22146226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
    Foote BS; Spooner LM; Belliveau PP
    Ann Pharmacother; 2011 Sep; 45(9):1085-93. PubMed ID: 21828346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients.
    Zeuzem S; DeMasi R; Baldini A; Coate B; Luo D; Mrus J; Witek J
    J Hepatol; 2014 Jun; 60(6):1112-7. PubMed ID: 24486089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors.
    Kozielewicz D; Dybowska D; Karwowska K; Wietlicka-Piszcz M
    Expert Opin Drug Saf; 2015; 14(12):1815-25. PubMed ID: 26513231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection].
    Macías J; Rivero A
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():33-6. PubMed ID: 24063901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A modified ribavirin-free interferon therapy with boceprevir in post-liver transplant recurrent hepatitis C.
    Maticic M; Luznik Z; Stepec S; Popovic P; Snedec N; Poljak M; Stanisavljevic D
    J Clin Gastroenterol; 2014; 48(5):464-5. PubMed ID: 24275712
    [No Abstract]   [Full Text] [Related]  

  • 31. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
    Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
    Pungpapong S; Aqel BA; Koning L; Murphy JL; Henry TM; Ryland KL; Yataco ML; Satyanarayana R; Rosser BG; Vargas HE; Charlton MR; Keaveny AP
    Liver Transpl; 2013 Jul; 19(7):690-700. PubMed ID: 23696372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
    Flamm SL; Lawitz E; Jacobson I; Bourlière M; Hezode C; Vierling JM; Bacon BR; Niederau C; Sherman M; Goteti V; Sings HL; Barnard RO; Howe JA; Pedicone LD; Burroughs MH; Brass CA; Albrecht JK; Poordad F
    Clin Gastroenterol Hepatol; 2013 Jan; 11(1):81-87.e4; quiz e5. PubMed ID: 23064222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations)].
    Crespo G; Lens S
    Gastroenterol Hepatol; 2012 May; 35(5):337-43. PubMed ID: 22349607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs.
    Arain A; Bourgeois S; de Galocsy C; Henrion J; Deltenre P; d'Heygere F; George C; Bastens B; Van Overbeke L; Verrando R; Bruckers L; Mathei C; Buntinx F; Van Vlierberghe H; Francque S; Laleman W; Moreno C; Janssens F; Nevens F; Robaeys G
    J Med Virol; 2016 Jan; 88(1):94-9. PubMed ID: 26121975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP; Markova AA; Calle Serrano B; Cornberg M
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Boceprevir for HCV in patients with HIV: where next?
    Osinusi A; Naggie S
    Lancet Infect Dis; 2013 Jul; 13(7):563-4. PubMed ID: 23768748
    [No Abstract]   [Full Text] [Related]  

  • 38. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
    Forestier N; Zeuzem S
    Liver Int; 2012 Feb; 32 Suppl 1():44-50. PubMed ID: 22212571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients.
    Burney T; Dusheiko G
    Expert Rev Anti Infect Ther; 2011 Feb; 9(2):151-60. PubMed ID: 21143041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New agents for the treatment of hepatitis C].
    Buti M; Homs M
    Enferm Infecc Microbiol Clin; 2012 Mar; 30(3):147-50. PubMed ID: 22118805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.